INCREASED CHANCES OF PREGNANCY AFTER MYOMECTOMY IN ART PROGRAMS
https://doi.org/10.21518/2079-701X-2017-13-138-142
Abstract
Myoma of the uterus occupies the third place in the structure of gynecological pathology, second only to inflammatory diseases, the main symptoms of uterine fibroids are profuse menstruation, pelvic pain, infertility, impaired function of neighboring organs characteristic of tumors of large sizes. Treatment of uterine fibroids «an urgent problem of modern gynecology», despite the variety of therapeutic techniques. Uterine myoma is a frequent cause of infertility, the pathogenesis of which is not fully understood. Recently, as a drug of choice for the purpose of adjuvant therapy of uterine fibroids, the drug mifepristone has been widely used, which has a high therapeutic efficiency, which contributes to the realization of the reproductive function in the conduct of organ-saving operations.
About the Authors
A. Z. Khashukoyeva
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России
Russian Federation
Russian Federation
MD,
M. I. Agaeva
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России
Russian Federation
Russian Federation
M. Z. Dugieva
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России
Russian Federation
Russian Federation
MD,
K A. Ermilova
K.A. ERMILOVA1, T.N. SUKHOVA2
Russian Federation
Russian Federation
T. N. Sukhova
Российский геронтологический научно-клинический центр Российского национального исследовательского медицинского университета им. Н.И. Пирогова Минздрава России
Russian Federation
Russian Federation
References
1. Миома матки: клинические рекомендации (протокол лечения). М.: Минздрав РФ, 2015.
2. Подзолкова Н.М., Колода Ю.А., Коренная В.В., Кайибханова К.Н. Эффективность вспомогательных репродуктивных технологий при миоме матки (обзор литературы). Пробл. репродукции, 2015, 2: 60–64.
3. Радзинский В.Е., Ордиянц И.М. Хорольский В.А. Лечение миомы: вариативность как проблема. Сравнительная эффективность и безопасность двух схем мифепристона для медикаментозной терапии миомы матки. Status Praesens, 2015, 6(26): 30–41.
4. Радзинский В.Е., Тотчиев Г.Ф. Миома матки: курс на органосохранение. Информационный бюллетень. М.: Редакция журнала StatusPraesens, 2014. 24 с.
5. Тихомиров А.Л., Лубнин Д.М., Кочарян А.А. Современный алгоритм комплексного консервативного лечения миомы матки. Репродуктивное здоровье женщины, 2007, 9(6): 13–15.
6. AAGL Practice Report: practice guidelines for diagnosis and management of submucous leiomyomas. J. Min. Invasive Gynecol., 2012, 19(2): 152–171.
7. Bosteels J, Kasius J, Weyers S, Broekmans FJ et al. Hysteroscopy for treating suspected abnormalities of the cavity of the womb in women having difficulty becoming pregnant. The Cochrane Collaboration. 2015. URL: http://www. cochrane.org/CD009461/ MENSTR_hysteroscopy-for-treating-suspected-abnormali-ties-ofthe-cavity-of-the-womb-in-women-having-difficulty-becom-ing-pregnant (дата обращения – 15.08.2016).
8. Metwally M, Cheong YC, Horne AW. Surgical treatment of fibroids for subfertility. Cochrane Database Syst. Rev., 2012: CD003857.
9. Moon JW, Kim CH, Kim JB, Kim SH et al. Alterations in uterine hemodynamics caused by uterine fibroids and their impact on in vitro fertilization outcomes. Clin. Exp. Reprod. Med., 2015, 42(4): 163–168.
10. Moravek MB, Yin P, Ono M, Coon JS 5th et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum. Reprod. Update., 2015, 21(1): 1–12.
11. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil. Steril., 2009, 91(4): 1215–1223.
12. Purohit P, Vigneswaran K. Fibroids and infertility. Curr. Obstet. Gynecol. Rep., 2016, 5: 81–88.
13. Shen Q, Hua Y, Jiang W, Zhang W et al. Mifepristone and uterine leiomyoma. Fertil. Steril., 2013, 100(10): 1722–1726.
14. Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y et al. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and metaanalysis. Hum. Reprod., 2010, 25(2): 418– 429.
15. Yan L, Ding L, Li C, Wang Y et al. Effect of fibroids not distorting the endometrial cavity on the outcome of in vitro fertilization treatment: a retrospective cohort study. Fertil. Steril., 2014, 101(3): 716–721.
16. Rein MS, Friedman AJ et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet. Gynecol., 1991, 77(6): 923–926.
17. Tiltman AJ. Smooth muscle neoplasms of the uterus. Curr. Opin. Obstet. Gynecol., 1991, 9(1): 48–51.
18. Kawaguchi KS Fujii et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynecol., 1989, 160(3): 637– 641.
19. Fujimoto J, Ichigo S et al. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer. Lett., 1998, 130(1–2): 115– 120.
20. Friedman AJ. Clinical experience in the treatment of fibroids with leuprolide and other GnRH agonists. Obstet. Gynecol. Surv., 1989, 44(5): 311–313.
21. Hyder SM, Huang JC et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ. Health Perspec., 2000, 108(Suppl. 5): 785–790.
22. Shimomura Y, Matsuo H et al. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J. Clin. Endocrinol. Metab., 1998, 83(6): 2192–2198.
23. Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения: монография. М., 2013.
24. Kelly RW, King AE, Critchley HOD. Inflammatory mediators and endometrial function – focus on the perivascular cell. Reprod. Immunol., 2002, 57: 81–93.
25. Baird DT, Brown A, Critchley HOD et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod., 2003, 18: 61–68.
26. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive Gynecol., 2005, 12: 227–233.
27. Exavery A, Mrema S, Shamte A. Levels and correlates of non-adherence to WHO recommended inter-birth intervals in Rufiji, Tanzania. BMC Pregn. Child., 2012, 12: 152.
28. Strassmann BI. The biology of menstruation in Home sapiens: Total lifetime menses, fecundity, and nonsynchrony in a natural-fertility population. Curr. Anthropol., 1997, 38: 123–129.
29. McDougall I, Brown FH, Fleagle JG. Stratigraphic placement and age of modern humans from Kibish, Ethiopia. Nature, 2005, 433: 733–736.
30. Ищенко А.И., Ботвин М.А., Ланчинский В.И. Миома матки: этиология, патогенез, диагностика, лечение. М.: Издательский дом «Видар-М», 2010. 244 с.
31. Mauro A, Martelli A, Berardinelli P et al. Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation. PLoS One,2014, 9(4): e95910.
32. Петракова С.А. Возможности миомэктомии в коррекции репродуктивного здоровья женщин с миомой матки. Акушерство и гинекология, 2009, 1: 30–31.
Review
For citations:
Khashukoyeva AZ, Agaeva MI, Dugieva MZ, Ermilova KA, Sukhova TN. INCREASED CHANCES OF PREGNANCY AFTER MYOMECTOMY IN ART PROGRAMS. Meditsinskiy sovet = Medical Council. 2017;(13):138-142. (In Russ.) https://doi.org/10.21518/2079-701X-2017-13-138-142
Views:
620
Email this article 